Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹220 Cr
verified against source
Revenue YoY
-21%
reported change
EBITDA
₹72 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Clean Science reported a weak Q3 FY26 with consolidated revenue of ₹216 crore, down 21% YoY, driven by volume decline of 19% and pricing pressure of 2%. EBITDA margin contracted to 33% (consolidated) and PAT stood at ₹46 crore. The performance chemicals segment was hit hardest, with MEHQ and BHA volumes declining due to Chinese competition and tariff-related destocking in North America. The FMCG segment lost a key customer in China for 4-MAP. On the positive side, the HALS business grew 55% YoY to 810 tons, and the subsidiary Clean Phenino reached breakeven. The new hydroquinone/catechol plant was commercialized in December, expected to improve margins for downstream products. Management refrained from providing near-term margin guidance, citing continued uncertainty from tariffs and Chinese pricing. Risk: Further pricing erosion from Chinese overcapacity could persist for multiple quarters.
Colored figures show movement against the previous available record.
Guidance to track
- The PC2 plant is expected to start production by May-June 2026, with revenues beginning in Q4 FY27 after teething issues and customer approvals.
- Management reiterated its guidance of achieving 50% utilization for the HALS plant over a 2-year period from commercialization.
- Management stated that the Bhoop family is unlikely to sell any further shares in the next couple of years, even after the lock-in period.
Risks flagged
- Chinese competitors have increased capacity in hydroquinone and MEHQ, driving prices to all-time lows and pressuring Clean Science's margins.
- US tariffs of 55% on Indian benzophenone have reduced offtake from Indian customers, and tariff uncertainty is causing destocking in North America and Europe.
- A Chinese customer for 4-MAP has backward integrated, resulting in permanent volume loss. Management confirmed the customer is 'dead' and will not return.
- Despite public announcements of price hikes by global HALS majors, these have not been implemented, keeping margins under pressure.
Key quotes
- The current quarter was marked by challenging and uncertain business environment driven by muted customer uptake, pricing pressure and tariff related uncertainties along with incremental capacities of some of the products especially in China.
- I think that customer is dead I mean it's lost for us because they have backward integrated.
- We are still not at the most optimum situation because I think we are still improving... there is still more scope for us.
Research modules